Literature DB >> 10589960

Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells.

L Branco1, P Barren, S Y Mao, D Pfarr, R Kaplan, C Postema, S Langermann, S Koenig, S Johnson.   

Abstract

CD2 is a 50-kDa transmembrane glycoprotein that plays an important role in T and natural killer (NT) lymphocyte functions. CD2 serves as both an adhesion molecule and as a costimulatory molecule through interactions with its ligand, CD58, on antigen presenting or target cells. Consistent with earlier studies using a rat anti-CD2 mAb, we have shown that treatment of alloantigen stimulated T lymphocytes with a humanized mAb, MEDI-507 (IgG1, kappa), induced hyporesponsiveness to subsequent stimulation with alloantigen but not to mitogen (phytohemagglutinin). Fluorescence-activated cell sorting analysis of cells from mixed lymphocyte reaction (MLR) treated with MEDI-507 revealed pronounced deletion of T and NK cells, consistent with lack of proliferation in the MLR. MEDI-507 F(ab')2 fragments did not have inhibitory activity or induce deletion of lymphocytes in the MLR. Removal of the NK cell subset by magnetic bead depletion using anti-CD16 and anti-CD56 mAbs eliminated both the T cell deletion and the inhibitory effect. Reconstitution of NK depleted responder populations using autologous NK cells restored the MEDI-507-mediated deletion activity to levels measured in the original MLR. Formaldehyde-fixed NK cells failed to mediate the MEDI-507-induced deletion effect. Altogether, our studies indicate that activated T cells with MEDI-507 bound to CD2 are preferential targets for autologous NK cells through a nonapoptotic cytotoxic mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589960     DOI: 10.1097/00007890-199911270-00026

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation.

Authors:  Jining Liu; Jinfa Ying; Vincent T K Chow; Victor J Hruby; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2005-10-06       Impact factor: 7.446

Review 2.  New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression.

Authors:  Scott M Steward-Tharp; Yun-jeong Song; Richard M Siegel; John J O'Shea
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 3.  Current and emerging systemic treatment strategies for psoriasis.

Authors:  Philip M Laws; Helen S Young
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 4.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

5.  Structure-based identification of inhibitors disrupting the CD2-CD58 interactions.

Authors:  Neha Tripathi; Laurence Leherte; Daniel P Vercauteren; Adèle D Laurent
Journal:  J Comput Aided Mol Des       Date:  2021-02-03       Impact factor: 3.686

6.  Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.

Authors:  Manuel A Podestà; Christian Binder; Felix Sellberg; Susan DeWolf; Brittany Shonts; Siu-Hong Ho; Aleksandar Obradovic; Elizabeth Waffarn; Nichole Danzl; David Berglund; Megan Sykes
Journal:  Am J Transplant       Date:  2019-08-13       Impact factor: 9.369

7.  Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro.

Authors:  Christian Binder; Felix Sellberg; Filip Cvetkovski; Erik Berglund; David Berglund
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

8.  Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Christian Binder; Felix Sellberg; Filip Cvetkovski; Stefan Berg; Erik Berglund; David Berglund
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

9.  Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques - an experimental study.

Authors:  Erik Berglund; Paula Alonso-Guallart; Makenzie Danton; Felix Sellberg; Christian Binder; Robin Fröbom; David Berglund; Nathaly Llore; Hiroshi Sakai; Alina Iuga; Dilrukshi Ekanayake-Alper; Keith A Reimann; David H Sachs; Megan Sykes; Adam Griesemer
Journal:  Transpl Int       Date:  2019-11-15       Impact factor: 3.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.